## CL: Colgate-Palmolive Company - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_10 -2.6% below STRENGTH zone (3.0-6.0%); PEG 3.05 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.75)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Did Colgate-Palmoliveâ€™s (CL) Dividend King Status and Q4 Preview Just Redefine Its Defensive Edge?**
- Source: Simply Wall Street | 20260106T182904 | Somewhat-Bullish | Relevance: 100%
- Colgate-Palmolive's status as a Dividend King and its focus on science-based innovation and cost initiatives are gaining attention ahead of its Q4 earnings. This reinforces its reputation as a defensive consumer staples leader, with new innovation and emerging market execution expected to influence its investment narrative. Despite strong dividend reliability and margin resilience, persistent consumer caution remains a key risk for volume growth.

**2. Colgate-Palmolive (CL) Remains Overweight as JPMorgan Sees Headwinds Easing in 2026**
- Source: Insider Monkey | 20260105T215800 | Somewhat-Bullish | Relevance: 100%
- JPMorgan has maintained its Overweight rating on Colgate-Palmolive (CL) and increased its price target to $88, anticipating an easing of economic headwinds in 2026. The firm notes that while 2025 presented challenges for household and personal care, improvements are expected as pressures like strain on low-income consumers and tariffs are lapped. Colgate-Palmolive, a "Dividend King" with 63 consecutive years of dividend increases, focuses on everyday essentials, innovation, and strategic pricing to maintain market position and manage costs.

**3. Colgate-Palmolive Company (NYSE:CL) is a favorite amongst institutional investors who own 86%**
- Source: Simply Wall Street | 20260104T143646 | Somewhat-Bullish | Relevance: 100%
- Institutional investors own 86% of Colgate-Palmolive Company (NYSE:CL), indicating that their trading actions significantly influence the stock price. The top 24 shareholders collectively hold 50% of the business, suggesting broad ownership among institutions rather than concentrated control, with the largest single shareholder being The Vanguard Group, Inc. at 10%. Insider ownership is less than 1%, but their combined holdings are valued at US$70 million, while the general public holds a 14% stake.

**4. Colgate-Palmolive Company (NYSE:CL) is a favorite amongst institutional investors who own 86%**
- Source: Simply Wall Street | 20260104T140745 | Somewhat-Bullish | Relevance: 100%
- Institutional investors own 86% of Colgate-Palmolive Company (NYSE:CL), indicating their strong interest and potential influence on the stock price. The Vanguard Group is the largest shareholder with 10%, and the top 24 shareholders collectively own 50% of the company. Individual investors hold a smaller, but still significant, portion at 14%, while insiders own less than 1%.

**5. Colgate-Palmolive (CL) Upgraded to Overweight by Piper Sandler**
- Source: GuruFocus | 20260106T213920 | Bullish | Relevance: 100%
- Piper Sandler has upgraded Colgate-Palmolive (CL) to Overweight, increasing its price target to $88 from $82, citing that recent Q4 challenges are already priced into the stock. The upgrade is driven by potential growth acceleration in 2026, particularly in emerging markets where Colgate-Palmolive has significant exposure. Despite a high debt-to-equity ratio, the company exhibits strong financial health and promising valuation metrics, including a P/E ratio near its 10-year low.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | JP Morgan | $88 | $87 | +1% |
| 2025-12-11 | Argus Research | $0 | $0 | 0% |
| 2025-12-09 | RBC Capital | $88 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | JP Morgan | main | Overweight |
| 2025-12-11 | Argus Research | down | Hold |
| 2025-12-09 | RBC Capital | up | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 7 ($0.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.8% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.2%)
- Blackrock Inc.: 8.6% (+0.5%)
- State Street Corpora: 6.0% (+0.2%)
- Price (T.Rowe) Assoc: 4.0% (-11.5%)
- Geode Capital Manage: 2.7% (+4.1%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.4% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 3.1x requires aggressive growth execution.
3. Long-term trend broken: trading 9.2% below SMA200.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.05 signals overvaluation risk, limited margin of safety. Forward P/E 20.1x stretched relative to 5% growth. Quality metrics strong (ROE 294%, ROA 15%). Balance sheet: $1.1B free cash flow. Institutional flow bearish (5 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $62.4B |
| Beta | 0.30 |
| 52W Range | $74.55 - $100.18 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.05 |
| Forward P/E | 20.1 |
| Current P/E | 21.1 |
| YoY Growth | 5.0% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -0.2% to -2.6% (-2.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.6pp (needs >3.0% for momentum thesis). Below SMA200 (0.91x), long-term trend not supportive. RSI neutral at 42. OFD pattern: +MLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.56% (CS: 11) | Weak |
| RSI_14 | 42.4 | Neutral |
| MACD Histogram | -0.23 | Bearish |
| vs SMA20 | 0.984x | Below |
| vs SMA50 | 0.985x | Below |
| vs SMA200 | 0.908x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $77.19
- **Stop Loss:** $74.75 (3.2% risk)
- **Target:** $79.63 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 225
- **Position Value:** $17,367.75
- **Portfolio %:** 17.37%
- **Risk Dollars:** $550.00
- **Risk Per Trade:** 0.55%
- **Modifiers:** L1 110% | L2 50% | Combined 0.55x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-01-30 (Est: $0.91)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.89 | $0.91 | +2.4% |
| 2025Q2 | $0.89 | $0.92 | +2.8% |
| 2025Q1 | $0.86 | $0.91 | +6.1% |
| 2024Q4 | $0.89 | $0.91 | +2.3% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_10*